Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (Entresto)
2017-004909-41Phase 2Active
- Sponsor
- Akershus University Hospital
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer and heart failure (HF) comparing Entresto with Placebo (2 arms). Primary endpoint: Change in left ventricular ejection fraction by CMR. Started Jan 2018; status: active.
02
Drugs
sacubitril + valsartan
03
Conditions
breast cancerheart failure (HF)
Beyond the preview
Go deeper on 2017-004909-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004909-41.